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Dear Editor
Pulse oximetry screening for critical congenital heart defects has consistent test accuracy1, meets 
the criteria for a universal screening test1 and reduces mortality.2
In May 2019 the National Screening Committee (NSC) announced a public consultation on its 
decision not to introduce routine pulse oximetry screening (POS) for critical congenital heart defects 
(CCHD) in all newborn babies.1
The main reasons given for the NSC’s decision are outlined in the consultation covernote as follows:
i) ‘A positive result from pulse oximetry will generate some harms, including: parental 
anxiety, a longer stay in hospital, possible transfer to the neonatal unit [NNU], further 
tests to assess for non-symptomatic conditions. 
ii) For many of these babies the further investigations will be unnecessary and the baby will 
be identified as healthy. This is a false positive result. 
iii) For babies with CHD [congenital heart defects] or other non-cardiac condition it is not 
clear that investigations and identification of these conditions will lead to any better 
outcome than a diagnosis at the time the baby becomes symptomatic.’
Following the NSC UK PulseOx pilot study3 and in the absence of comparator data, the NSC convened 
an expert Workgroup to provide a pragmatic consensus view on the questions relating to outcomes, 
harms and benefits. As clinical members of a Workgroup invited by the NSC to offer expert advice on 
these issues at a meeting in June 2018, 4 we are disappointed that the NSC decision not to 
recommend screening for these same issues does not reflect the conclusions that we reached.
The purpose of the workshop was …‘to look at [the] conditions [identified by POS] and discuss, with 
an expert group, what would have been the natural history of unscreened babies and whether all 
would have needed treatment and whether there may have been unnecessary harm.’
Although the NSC decision document does not contain any data on the numbers of babies that 
would be affected by POS, our discussions - which were based on data from the NSC PulseOx pilot 
study (2015)3 - considered these in detail. 
We identified that out of 32 597 babies screened, 114 babies (0.35%) who tested positive were 
admitted to NNU, of which 8 had a CCHD (5 babies had non-critical CHD but were not admitted). A 
further 82 of the babies admitted to NNU (72% of the total admitted) had a significant non-cardiac 
illness.  Although this group are technically false positives for the purposes of screening for CCHD, 8 
distinct conditions were identified (congenital pneumonia, persistent pulmonary hypertension of the 
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newborn, culture positive and culture negative sepsis, meconium aspiration, pneumothorax, 
transient tachypnoea of the newborn and respiratory distress syndrome) which required treatment; 
only 22 babies (0.07% of all babies screened) were healthy (transitional circulation [TC]).4
We considered the relative benefits and harms in babies who were diagnosed with the eight non-
cardiac conditions as a result of POS. We concluded that in six of the eight conditions there was clear 
benefit to early identification (i.e. highly likely to result in improved outcome). In one condition 
(culture-negative sepsis) there was the potential for overtreatment but clear benefit to the genuine 
cases and we concluded ‘it is better to treat suspected cases as the outcome of non-treatment of 
sepsis is serious’. For babies with TC and minor pneumothoraces (Ptx) we concluded that there was 
no benefit and these babies were subjected to the harms of delayed discharge (12 hours maximum) 
and unnecessary investigation (blood tests and x-rays) but this accounted for only 23 babies (22 TC 
and 1 Ptx) - 0.07% of all babies screened.4
In our opinion, these figures demonstrate that there are clear benefits in the majority of those false 
positives detected by POS who are admitted to NNU, (early detection and timely intervention) and 
there are modest harms (delayed discharge, overtreatment) in a minority.
These views are not reflected in the NSC’s statement and we urge them to review their decision not 
to introduce routine newborn pulse oximetry screening for critical congenital heart defects in light of 
our conclusions.
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